{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:51:00Z","timestamp":1782921060086,"version":"3.54.5"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.tox.2023.153544","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T01:56:13Z","timestamp":1683597373000},"page":"153544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity"],"prefix":"10.1016","volume":"492","author":[{"given":"Jun","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2023.153544_bib1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.transproceed.2020.01.030","article-title":"Long-term effects of the replacement of calcineurin inhibitors with everolimus and mycophenolate in patients with calcineurin inhibitor-related nephrotoxicity","volume":"52","author":"Acquaro","year":"2020","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.tox.2023.153544_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5500\/wjt.v6.i1.125","article-title":"Post-transplant dyslipidemia: mechanisms, diagnosis and management","volume":"6","author":"Agarwal","year":"2016","journal-title":"World J. Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.2015.312","article-title":"Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration","volume":"89","author":"Amador","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.clpt.2004.01.009","article-title":"CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation","volume":"75","author":"Anglicheau","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tox.2023.153544_bib5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.ki.5001649","article-title":"Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction","volume":"70","author":"Anglicheau","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.taap.2009.05.028","article-title":"Vitamin E protects against the mitochondrial damage caused by cyclosporin A in LLC-PK1 cells","volume":"239","author":"de Arriba","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tox.2023.153544_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.toxlet.2013.01.007","article-title":"Cyclosporine A-induced apoptosis in renal tubular cells is related to oxidative damage and mitochondrial fission","volume":"218","author":"de Arriba","year":"2013","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.tox.2023.153544_bib8","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1523-1755.2003.00175.x","article-title":"Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy","volume":"64","author":"Bakker","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1592\/phco.23.6.788.32180","article-title":"Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction","volume":"23","author":"Baroletti","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tox.2023.153544_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ki.1987.166","article-title":"Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity","volume":"32","author":"Barros","year":"1987","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ki.1996.415","article-title":"Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy","volume":"50","author":"Bennett","year":"1996","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2008.324","article-title":"Endothelin ETB receptor heterodimerization: beyond the ETA receptor","volume":"74","author":"Boesen","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib13","doi-asserted-by":"crossref","first-page":"F160","DOI":"10.1152\/ajprenal.90567.2008","article-title":"Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death","volume":"296","author":"Bouvier","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.tox.2023.153544_bib14","article-title":"Endothelin-1 receptor antagonists protect the kidney against the nephrotoxicity induced by cyclosporine-A in normotensive and hypertensive rats","volume":"51","author":"Caires","year":"2017","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.tox.2023.153544_bib15","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors","volume":"2","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.tox.2023.153544_bib16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.1995.161","article-title":"A controlled trial of cyclosporine in patients with progressive membranous nephropathy","volume":"47","author":"Cattran","year":"1995","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib17","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib18","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1399-0012.2005.00357.x","article-title":"Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients","volume":"19","author":"Cauduro","year":"2005","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib20","first-page":"F31","article-title":"Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A","volume":"269","author":"Charuk","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.tox.2023.153544_bib21","first-page":"F542","article-title":"Endothelin-1 mRNA in glomerular and epithelial cells of kidney","volume":"265","author":"Chen","year":"1993","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.tox.2023.153544_bib22","doi-asserted-by":"crossref","first-page":"F789","DOI":"10.1152\/ajprenal.00254.2020","article-title":"Calcineurin A-alpha suppression drives nuclear factor-kappaB-mediated NADPH oxidase-2 upregulation","volume":"320","author":"Cheriyan","year":"2021","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.tox.2023.153544_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0163-7258(93)90059-M","article-title":"Cyclosporin metabolism in transplant patients","volume":"57","author":"Christians","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tox.2023.153544_bib24","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/ajt.14632","article-title":"The TWEAK\/Fn14 pathway is required for calcineurin inhibitor toxicity of the kidneys","volume":"18","author":"Claus","year":"2018","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12964-020-00636-4","article-title":"Calcineurin","volume":"18","author":"Creamer","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.tox.2023.153544_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(86)90355-7","article-title":"Cyclosporin in therapeutic doses increases renal allograft vascular resistance","volume":"2","author":"Curtis","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.tox.2023.153544_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.tox.2023.153544_bib28","first-page":"1705","article-title":"Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits","volume":"151","author":"del Moral","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tox.2023.153544_bib29","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1600-6143.2012.04081.x","article-title":"Nox2 is a mediator of chronic CsA nephrotoxicity","volume":"12","author":"Djamali","year":"2012","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib30","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1097\/00007890-199806150-00019","article-title":"Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report","volume":"65","author":"Ducloux","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.tox.2023.153544_bib31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1523-1755.1998.00050.x","article-title":"Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy","volume":"54","author":"Duymelinck","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ndt\/gfg434","article-title":"The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression","volume":"19","author":"Einecke","year":"2004","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib33","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0024-3205(98)00227-6","article-title":"Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein","volume":"62","author":"Fakata","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/j.tox.2023.153544_bib34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.tox.2023.153544_bib35","doi-asserted-by":"crossref","first-page":"220S","DOI":"10.1016\/j.transproceed.2004.01.028","article-title":"Cyclosporine nephrotoxicity","volume":"36","author":"Fellstrom","year":"2004","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.tox.2023.153544_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/352803a0","article-title":"Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A","volume":"352","author":"Flanagan","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.tox.2023.153544_bib37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ki.1992.346","article-title":"Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity","volume":"42","author":"Fogo","year":"1992","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0009-9120(91)90084-R","article-title":"Pharmacology and pharmacokinetics of cyclosporine","volume":"24","author":"Freeman","year":"1991","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.tox.2023.153544_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1902\/jop.2014.130285","article-title":"Role of transforming growth factor-beta1 in cyclosporine-induced epithelial-to-mesenchymal transition in gingival epithelium","volume":"86","author":"Fu","year":"2015","journal-title":"J. Periodontol."},{"key":"10.1016\/j.tox.2023.153544_bib40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1681\/ASN.2015080936","article-title":"Stress response gene Nupr1 alleviates cyclosporin A nephrotoxicity in vivo","volume":"28","author":"Galichon","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.tp.0000185305.63759.d3","article-title":"ACE gene D\/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients","volume":"81","author":"Gallon","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.tox.2023.153544_bib42","first-page":"398","article-title":"Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study","volume":"146","author":"Garcia del Moral","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tox.2023.153544_bib43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000101999","article-title":"Endothelin-1 induces NF-kappaB via two independent pathways in human renal tubular epithelial cells","volume":"27","author":"Gerstung","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib44","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/lt.500030409","article-title":"Hyperlipidemia in liver transplant recipients: prevalence and risk factors","volume":"3","author":"Gisbert","year":"1997","journal-title":"Liver Transpl. Surg."},{"key":"10.1016\/j.tox.2023.153544_bib45","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1161\/01.HYP.37.4.1171","article-title":"Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1","volume":"37","author":"Gomez-Garre","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.tox.2023.153544_bib46","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00204-016-1830-8","article-title":"TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity","volume":"91","author":"Gonzalez-Guerrero","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2023.153544_bib47","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000101367","article-title":"Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs","volume":"27","author":"Goumenos","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib48","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00467-012-2403-6","article-title":"Endoplasmic reticulum stress with low-dose cyclosporine in frequently relapsing nephrotic syndrome","volume":"28","author":"Hama","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996","volume":"342","author":"Hariharan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tox.2023.153544_bib50","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1046\/j.1523-1755.1998.00095.x","article-title":"Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells","volume":"54","author":"Hauser","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib51","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1681\/ASN.2004100882","article-title":"ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation","volume":"16","author":"Hauser","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib52","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1681\/ASN.2010060673","article-title":"Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients","volume":"22","author":"Hazzan","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib53","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1046\/j.1523-1755.1998.00202.x","article-title":"Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line","volume":"54","author":"Healy","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib54","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clpt.2004.08.022","article-title":"Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes","volume":"76","author":"Hesselink","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tox.2023.153544_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13033","article-title":"Cyclosporine A induces endothelin-converting enzyme-1: studies in vivo and in vitro","volume":"223","author":"Heyman","year":"2018","journal-title":"Acta Physiol."},{"key":"10.1016\/j.tox.2023.153544_bib56","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00467-008-0792-3","article-title":"Therapies for steroid-resistant nephrotic syndrome","volume":"23","author":"Hodson","year":"2008","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib57","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(95)90520-0","article-title":"Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation","volume":"345","author":"Hollander","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.tox.2023.153544_bib58","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000351648","article-title":"Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence","volume":"37","author":"Issa","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib59","first-page":"F756","article-title":"Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues","volume":"270","author":"Jette","year":"1996","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.tox.2023.153544_bib60","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00041552-200211000-00006","article-title":"Sirolimus (Rapamune) in renal transplantation","volume":"11","author":"Johnson","year":"2002","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.tox.2023.153544_bib61","article-title":"Nephrotoxicity of calcineurin inhibitors in kidney epithelial cells is independent of NFAT signaling","volume":"12","author":"Karolin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tox.2023.153544_bib62","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1681\/ASN.V11101910","article-title":"A meta-analysis of immunosuppression withdrawal trials in renal transplantation","volume":"11","author":"Kasiske","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib63","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MOL.0000000000000363","article-title":"Hyperlipidaemia in immunosuppression","volume":"27","author":"Kockx","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.tox.2023.153544_bib64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1523-1755.2001.00782.x","article-title":"Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients","volume":"60","author":"Koziolek","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib65","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1034\/j.1600-6143.2001.10407.x","article-title":"Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine","volume":"1","author":"Kung","year":"2001","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib66","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s002040050627","article-title":"In vitro models to study mechanisms involved in cyclosporine A-mediated glomerular contraction","volume":"73","author":"L'Azou","year":"1999","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2023.153544_bib67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/ki.1997.328","article-title":"Cyclosporine and the renin-angiotensin axis","volume":"52","author":"Lee","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib68","first-page":"401","article-title":"Expression of apoptosis-related factors in chronic cyclosporine nephrotoxicity after cyclosporine withdrawal","volume":"25","author":"Li","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.tox.2023.153544_bib69","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bcp.2019.03.022","article-title":"Modulation of innate immunity by cyclosporine A","volume":"163","author":"Liddicoat","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tox.2023.153544_bib70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","article-title":"A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children","volume":"7","author":"Lieberman","year":"1996","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib71","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00007691-199510000-00008","article-title":"Measurement of AM19 and other cyclosporine metabolites in the blood of liver transplant patients with stable liver function","volume":"17","author":"Liu","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.tox.2023.153544_bib72","first-page":"2441","article-title":"Clinical nephrotoxicity induced by cyclosporin A combined with hormone therapy for nephrotic syndrome","volume":"34","author":"Liu","year":"2021","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.tox.2023.153544_bib73","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1053\/j.ajkd.2017.02.003","article-title":"AJKD atlas of renal pathology: calcineurin inhibitor nephrotoxicity","volume":"69","author":"Lusco","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.tox.2023.153544_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120259","article-title":"Geraniol protects against cyclosporine A-induced renal injury in rats: Role of Wnt\/beta-catenin and PPARgamma signaling pathways","volume":"291","author":"Mahmoud","year":"2022","journal-title":"Life Sci."},{"issue":"565\u2013585","key":"10.1016\/j.tox.2023.153544_bib75","article-title":"Drug-related dyslipidemia after renal transplantation","volume":"61","author":"Mathis","year":"2004","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.tox.2023.153544_bib76","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2169\/internalmedicine.43.668","article-title":"Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome","volume":"43","author":"Matsumoto","year":"2004","journal-title":"Intern. Med."},{"key":"10.1016\/j.tox.2023.153544_bib77","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/ndt\/gfh967","article-title":"Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells","volume":"20","author":"McMorrow","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib78","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5115\/acb.18.192","article-title":"Cyclosporin A aggravates hydrogen peroxide-induced cell death in kidney proximal tubule epithelial cells","volume":"52","author":"Moon","year":"2019","journal-title":"Anat. Cell Biol."},{"key":"10.1016\/j.tox.2023.153544_bib79","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00007890-199803150-00010","article-title":"Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy","volume":"65","author":"Mourad","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.tox.2023.153544_bib80","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM198409133111103","article-title":"Cyclosporine-associated chronic nephropathy","volume":"311","author":"Myers","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tox.2023.153544_bib81","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib82","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1248\/bpb.30.2371","article-title":"Association of cumulative cyclosporine dose with its irreversible nephrotoxicity in Japanese patients with pediatric-onset autoimmune diseases","volume":"30","author":"Nakamura","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.tox.2023.153544_bib83","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tox.2023.153544_bib84","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":"Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.tox.2023.153544_bib85","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras","volume":"100","author":"Nankivell","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.tox.2023.153544_bib86","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/FTD.0b013e31802c5cf5","article-title":"The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments","volume":"28","author":"Oellerich","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.tox.2023.153544_bib87","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00467-006-0301-5","article-title":"Primary focal segmental glomerular sclerosis in children: clinical course and prognosis","volume":"22","author":"Paik","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib88","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1111\/j.1600-6143.2008.02396.x","article-title":"Cyclosporine-induced endoplasmic reticulum stress triggers tubular phenotypic changes and death","volume":"8","author":"Pallet","year":"2008","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib89","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.taap.2008.01.019","article-title":"Response of human renal tubular cells to cyclosporine and sirolimus: a toxicogenomic study","volume":"229","author":"Pallet","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tox.2023.153544_bib90","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/08860220902882022","article-title":"Cyclosporine induces endothelin-1 mRNA synthesis and nitric oxide production in human proximal tubular epithelial cell cultures","volume":"31","author":"Papachristou","year":"2009","journal-title":"Ren. Fail"},{"key":"10.1016\/j.tox.2023.153544_bib91","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/ki.2010.69","article-title":"Paricalcitol attenuates cyclosporine-induced kidney injury in rats","volume":"77","author":"Park","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib92","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib93","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.13761119","article-title":"The evolving role of calcineurin inhibitors in treating lupus nephritis","volume":"15","author":"Peleg","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib94","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s002040050182","article-title":"In vitro metabolism of cyclosporin A with rabbit renal or hepatic microsomes: analysis by HPLC-FPIA and HPLC-MS","volume":"69","author":"Pham-Huy","year":"1995","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2023.153544_bib95","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","article-title":"A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome","volume":"43","author":"Ponticelli","year":"1993","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.healun.2010.08.001","article-title":"Endothelin-1 antagonism and nitric oxide augmentation prevents cyclosporine-induced vasomotor impairment","volume":"30","author":"Ramzy","year":"2011","journal-title":"J. Heart Lung Transpl."},{"key":"10.1016\/j.tox.2023.153544_bib97","first-page":"958","article-title":"Comparison of cyclophosphamide and cyclosporine in the treatment of steroid-resistant idiopathic nephrotic syndrome in children","volume":"32","author":"Rao","year":"2007","journal-title":"J. Cent. South Univ."},{"key":"10.1016\/j.tox.2023.153544_bib98","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ki.2010.93","article-title":"The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option?","volume":"77","author":"Reis","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib99","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1681\/ASN.V42168","article-title":"Effects of cyclosporine and its metabolites in the isolated perfused rat kidney","volume":"4","author":"Roby","year":"1993","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000187219","article-title":"Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy","volume":"63","author":"Rostoker","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.tox.2023.153544_bib101","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/bcp.13880","article-title":"Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation","volume":"85","author":"Sallustio","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tox.2023.153544_bib102","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.ki.5002638","article-title":"Phosphoinositide 3-kinase inhibitors protect mouse kidney cells from cyclosporine-induced cell death","volume":"73","author":"Sarro","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib103","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1046\/j.1523-1755.1999.00794.x","article-title":"Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis","volume":"56","author":"Shihab","year":"1999","journal-title":"Kidney Int."},{"issue":"Suppl. B","key":"10.1016\/j.tox.2023.153544_bib104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/eurheartj\/13.suppl_B.2","article-title":"Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model","volume":"13","author":"Smith","year":"1992","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.tox.2023.153544_bib105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S0100-879X2006000100003","article-title":"Relationship of cyclosporin and sirolimus blood concentrations regarding the incidence and severity of hyperlipidemia after kidney transplantation","volume":"39","author":"Spinelli","year":"2006","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.tox.2023.153544_bib106","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2217\/pgs-2017-0127","article-title":"Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients","volume":"18","author":"Sun","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.tox.2023.153544_bib107","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.diabres.2013.12.021","article-title":"Endothelin-1 mediated high glucose-induced epithelial-mesenchymal transition in renal tubular cells","volume":"104","author":"Tang","year":"2014","journal-title":"Diabetes Res Clin. Pract."},{"key":"10.1016\/j.tox.2023.153544_bib108","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000446293","article-title":"Endoplasmic reticulum stress predicts clinical response to cyclosporine treatment in primary membranous nephropathy","volume":"43","author":"Tao","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.tox.2023.153544_bib110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2008.03.026","article-title":"Cyclosporine A and rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma","volume":"358","author":"Tory","year":"2008","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.tox.2023.153544_bib111","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10456-008-9093-5","article-title":"Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1)","volume":"11","author":"van Beijnum","year":"2008","journal-title":"Angiogenesis"},{"key":"10.1016\/j.tox.2023.153544_bib112","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1523-1755.1998.00017.x","article-title":"A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases","volume":"54","author":"Vercauteren","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib113","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ki.1995.138","article-title":"Lipid peroxidation accompanies cyclosporine nephrotoxicity: effects of vitamin E","volume":"47","author":"Wang","year":"1995","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2023.153544_bib114","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00467-007-0586-z","article-title":"Correlation between finger-prick and venous ciclosporin levels: association with gingival overgrowth and hypertrichosis","volume":"22","author":"Webb","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5414\/CNP65393","article-title":"Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome","volume":"65","author":"Westhoff","year":"2006","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib116","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/clpt.2010.62","article-title":"Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up","volume":"88","author":"Woillard","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tox.2023.153544_bib117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1389200219666181031113505","article-title":"Metabolic pathway of cyclosporine A and its correlation with nephrotoxicity","volume":"20","author":"Wu","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.tox.2023.153544_bib118","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/pgs-2016-0171","article-title":"NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipients","volume":"18","author":"Xu","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.tox.2023.153544_bib119","first-page":"F1139","article-title":"Acute effect of cyclosporin on inner medullary blood flow in normal and postischemic rat kidney","volume":"258","author":"Yagil","year":"1990","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.tox.2023.153544_bib120","doi-asserted-by":"crossref","first-page":"F1311","DOI":"10.1152\/ajprenal.00072.2019","article-title":"p53-cyclophilin D mediates renal tubular cell apoptosis in ischemia-reperfusion-induced acute kidney injury","volume":"317","author":"Yang","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.tox.2023.153544_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197023","article-title":"Prediction of cyclosporin-mediated drug interaction using physiologically based pharmacokinetic model characterizing interplay of drug transporters and enzymes","volume":"21","author":"Yang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tox.2023.153544_bib122","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/14756366.2016.1149476","article-title":"Advances in plant-based inhibitors of P-glycoprotein","volume":"31","author":"Yu","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.tox.2023.153544_bib123","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e31827e6ad9","article-title":"CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition","volume":"95","author":"Zheng","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.tox.2023.153544_bib124","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1681\/ASN.2016030354","article-title":"Matrix metalloproteinase-7 is a urinary biomarker and pathogenic mediator of kidney fibrosis","volume":"28","author":"Zhou","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2023.153544_bib125","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1111\/ajt.16561","article-title":"Bioenergetic maladaptation and release of HMGB1 in calcineurin inhibitor-mediated nephrotoxicity","volume":"21","author":"Zmijewska","year":"2021","journal-title":"Am. J. Transpl."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X23001300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X23001300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:55:36Z","timestamp":1759535736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X23001300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":125,"alternative-id":["S0300483X23001300"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2023.153544","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2023.153544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153544"}}